ALK and lung cancer: Second generation ALK inhibitors including ceritinib, alectinib, and brigatinib target both therapy-naïve and crizotinib-resistant ALK positive lung cancers with acquired ALK mutations, and next generation ALK inhibitors are in various stages of clinical trials [22].